Date: 2014-12-11
Type of information: Nomination
Compound: member of the board of directors
Company: Asceneuron (Switzerland)
Therapeutic area: Neurodegenerative diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On December 11, 2014, Asceneuron announced that Prof. Raymond Hill, former Executive Director, Licensing and External Research, Europe for Merck&Co, has been appointed to the board of directors. In addition, Dr. Franz Hefti, experienced in development of therapeutics for Alzheimer’s disease and former Chief Scientific Officer of Avid Radiopharmaceuticals before its acquisition by Eli Lilly in 2010, has been appointed as special advisor to the board.
- Prof. Raymond Hill, PhD, is a veteran of the pharmaceutical industry and a well-regarded neuroscientist, who currently holds board seats and professorships. He also serves as President Emeritus of the British Pharmacological Society, as a co-opted member of Council, Academy of Medical Sciences and sits on the Advisory Council on Misuse of Drugs. Dr. Hill was Executive Director, Licensing and External Research, Europe for Merck Sharp and Dohme (MSD). He additionally had oversight responsibility for Neuroscience research at the MSD / Banyu Research Labs in Tsukuba, Japan. At MSD he chaired discovery project teams responsible for currently marketed products Maxalt and Emend. Dr. Hill is a non-executive director of Avilex and Orexo. He is visiting professor at Imperial College in London and the University of Bristol. Dr. Hill received BPharm and PhD degrees from the University of London and was elected to Fellowship of the Academy of Medical Sciences in 2005.
- Dr. Hefti is widely recognized as an expert in drug discovery and development for Alzheimer’s disease and other nervous system diseases. Dr. Hefti held senior management positions at Merck & Co. and Genentech. He carried out seminal research on therapeutic applications of neurotrophic factors while Associate Professor at the University of Miami, later becoming Professor at the University of Southern California. Dr. Hefti is President and Chief Operating Officer at NeuroPhage Pharmaceuticals , which is developing preclinical stage therapeutics for Alzheimer’s disease. Avid Radiopharmaceuticals, where Dr. Hefti was Chief Scientific Officer, developed an imaging diagnostic for Alzheimer’s disease before it was acquired by Eli Lilly in 2010. He also was Executive Vice President of Drug Development at Rinat Neuroscience, a company with antibody programs for Alzheimer’s disease and pain indications that was acquired by Pfizer in 2006. Dr. Hefti has published over 250 papers on neurotrophic factors and topics in neuropharmacology, as well as a textbook “Drug Discovery for Nervous System Diseases”. Dr. Hefti received his PhD from the University of Zurich and performed his postdoctoral research at the Massachusetts Institute of Technology in Boston and the Max Planck Institute in Munich.
Financial terms:
Latest news:
Is general: Yes
